Results 21 to 30 of about 10,900 (261)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review

BMJ Paediatrics Open, 2021
In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks.
Marina Davoli, Federico Marchetti, Antonio Addis, Valeria Belleudi, Marco Finocchietti   +4 more
doaj   +1 more source

Palivizumab

Reactions Weekly, 2018
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
  +5 more sources

Efficacy and Safety of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Disease: An Updated Systemic Review and Meta-Analysis

Cureus, 2023
This systematic review and meta-analysis aimed to summarize the current evidence regarding the efficacy and safety of palivizumab as a prophylaxis for respiratory syncytial virus (RSV) disease.
Khaled El-Atawi, D. De Luca, Ranagasamy Ramanathan, M. Sánchez Luna, S. Alsaedi, Muzafar Gani Abdul Wahab, Moataz Hamdi, Maysa Saleh   +7 more
semanticscholar   +1 more source

Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial

The Lancet Regional Health - Western Pacific, 2023
Summary Background Pediatric patients with certain rare diseases are at increased risk of severe respiratory syncytial virus (RSV) infection. However, the prophylactic use of anti-RSV antibody (palivizumab) in these patients is not indicated at present ...
M. Mori, K. Yoshizaki, S. Watabe, Mika Ishige, Akinari Hinoki, T. Kondo, T. Taguchi, Hisaya Hasegawa, T. Hatata, N. Tanuma, Kosuke Kirino, A. Hirakawa, T. Naruto, M. Imai, R. Koike, Kenichiro Hosoi, S. Kusuda   +16 more
semanticscholar   +1 more source

Does Prophylaxis Against Respiratory Syncytial Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?

Journal of Behçet Uz Children's Hospital, 2021
Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun, İbrahim İlker Çetin, Hazım Alper Gürsu   +2 more
doaj   +1 more source

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

Journal of Medical Economics, 2023
Background and objective To assess the cost-utility of palivizumab versus no prophylaxis in preventing severe respiratory syncytial virus (RSV) infection in Canadian moderate-to-late preterm (32–35 weeks’ gestational age) infants using an (i ...
B. Rodgers-Gray, J. Fullarton, X. Carbonell-Estrany, I. Keary, J. Tarride, B. Paes   +5 more
semanticscholar   +1 more source

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BMC Pediatrics, 2020
Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV).
Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore   +7 more
doaj   +1 more source

Linking pharmacy dispensing data to other administrative health datasets to measure the compliance and effectiveness of RSV immunoprophylaxis

International Journal of Population Data Science, 2018
Introduction Respiratory Syncytial Virus (RSV) causes considerable morbidity in children. RSV vaccines are in development, but the only current preventive measure is immunoprophylaxis with monoclonal antibody, palivizumab.
Hannah Moore, Tobias Strunk, Tasnim Abdalla, Tom Snelling, Peter Richmond, Anthony Keil, Nicholas de Klerk   +6 more
doaj   +1 more source

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation

Frontiers in Nutrition, 2020
Oral administration of engineered immunoglobulins has the potential to prevent enteric pathogen-induced diarrhea in infants. To prevent infection, these antibodies need to survive functionally intact in the proteolytic environment of the gastrointestinal
Baidya Nath P. Sah, Jiraporn Lueangsakulthai, Bum Jin Kim, Benjamin R. Hauser, Yeonhee Woo, Amy Olyaei, Molly Aloia, Ann O'Connor, Brian Scottoline, Manoj K. Pastey, David C. Dallas   +10 more
doaj   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants. [PDF]

Clin Pharmacol Ther
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Hu Z, Hellmann F, Zang X, Plock N, Parmar K, Railkar RA, Cheung SYA, Maas BM, Gheyas F.   +8 more
europepmc   +2 more sources